Here’s a groundbreaking revelation: Patients with kidney cancer brain metastases, often left with limited treatment options, may finally have a beacon of hope. A recent study has unveiled remarkable findings for cabozantinib (Cabometyx), a drug showing significant promise in this challenging area of oncology. But here's where it gets controversial—could this treatment redefine the standard of care for a condition historically excluded from major clinical trials?
At the International Kidney Cancer Symposium (IKCS) in Denver, researchers presented compelling data from a small prospective study. Among 25 patients with non-locally treated brain metastases from kidney cancer, 56% remained free of metastatic progression for at least 6 months when treated with cabozantinib. Even more striking, 71% of patients achieved a partial response, while eight others experienced stable disease. The median duration of brain metastasis response had yet to be reached, and extracranial responses were similarly encouraging. These results, reported by Dr. Sylvie Negrier of the Claude Berard Center and University of Lyon, highlight the drug’s prolonged efficacy, particularly in first-line patients or those without prior tyrosine kinase inhibitor (TKI) treatment.
And this is the part most people miss: The study also shed light on the aggressive subtype of kidney cancer known as fumarate hydratase-deficient renal cell carcinoma (FH-dRCC). A retrospective analysis revealed a 71% response rate when cabozantinib was combined with nivolumab (Opdivo). Dr. Maria Carlo of Memorial Sloan Kettering Cancer Center emphasized that these findings extend the combination’s efficacy beyond non-clear cell RCC, where it’s already a preferred treatment. But here’s the question: Is this combination the future of FH-dRCC treatment, or are we still missing something?
FH-dRCC, a rare subtype linked to mutations in the FH gene, has historically lacked effective treatments. While combinations like erlotinib and bevacizumab have shown some promise, recurrence remains a challenge. Recent trials pairing immune checkpoint inhibitors with TKIs have yielded impressive results, but the optimal combination and sequence of therapies are still up for debate. Could cabozantinib and nivolumab be the game-changer, or is there a better approach waiting to be discovered?
The phase II CABRAMET trial further solidified cabozantinib’s potential. Among 26 patients with metastatic RCC and non-locally treated brain metastases, the study met its primary endpoint of 6-month brain metastasis progression-free survival (PFS). The overall response rate was 61%, with particularly strong results in patients who had not received prior systemic therapy. Median brain metastasis PFS was 10.7 months, and median overall survival was 15 months. But is this enough to shift the paradigm for brain metastases treatment, or are we still relying too heavily on local therapies?
As we celebrate these advancements, it’s crucial to ask: Are we truly addressing the unmet needs of these patients, or is there more work to be done? Share your thoughts in the comments—do these findings mark a turning point in kidney cancer treatment, or is there still room for improvement?
